Japan's Mitshubishi Pharma loses Indian diabetes case

India's patent office dealt a blow to Mitsubishi Pharma by denying the Japanese company's application to patent the new diabetes drug teneligliptin, which will allow generic makers to move ahead with their plans to manufacture and market the drug.

The patent office in Kolkata denied the patent by saying it was "obvious and lacking (an) inventive step."

Teneligliptin was first launched by Glenmark in June and others like Zydus Cadila have also jumped on the bandwagon. India's Lupin, which opposed Mitsubishi's parent application, is also selling linagliptin, which is from the gliptin family.

As FiercePharmaAsia reported in November, the gliptin market in India is heating up with the move Zydus to introduce a low-cost teneligliptin under the name Tenglyn. The company priced its drug at 11 U.S. cents per pill while others in the market were priced at around 65 U.S. cents.

- here's the report from the Times of India

EJ Lane contributed to this report.

Suggested Articles

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

A decree includes tax incentives for certain generic drugmakers and uniform insurance standards that apply to both branded drugs and generics.